Antonella Tosti

TL;DR: It is shown that donor-versus-recipient natural killer (NK)–cell alloreactivity could eliminate leukemia relapse and graft rejection and protect patients against GVHD in human transplants and in mice, the pretransplant infusion of alloreactive NK cells obviated the need for high-intensity conditioning and reduced GV HD.

TL;DR: A GVL effector and engraftment facilitating mechanism, which is independent of T-cell-mediated GVH reactions, may be operational in HLA mismatched hematopoietic cell transplants.

TL;DR: Large numbers of donor T-cell clones specific for Aspergillus or cytomegalovirus antigens were generated and identified clones potentially responsible for causing GvHD by screening them for cross-reactivity against recipient mononuclear cells.

TL;DR: It is found that administration of G-CSF to recipients of T- cell-depleted hematopoietic transplants was associated with abnormal antigen-presenting cell functions and T-cell reactivity and elimination of postgrafting administration of ganulocyte colony-stimulating factor prevented immune dysregulation and accelerated functional immune recovery.

TL;DR: A novel anti- NKG2A antibody induced tumor cell death, suggesting that the antibody could be useful in the treatment of cancers expressing HLA-E, and it was found that immunodeficient mice, co-infused with human primary leukemia or Epstein-Barr virus cell lines and NKG1A+ natural killer cells, pre-treated with anti-human NKg2A, were rescued from disease progression.